Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


“ALTUVIIIO has exceeded my expectations.”
 

Deciding to switch

I first heard about ALTUVIIIO from my doctor, who said it might be a good fit for me. When I heard about its once-weekly prophylaxis schedule, I thought, “Yeah, that’s a good reason to switch.” I signed up for the free trial through the portal, and got put in contact with the ALTUVIIIO team to make the transition easy. 
 

Self-advocacy

I have always tried to stay positive, something my parents instilled in me growing up. But I know how easy it is to feel defeated and think there is no solution. Just know that it is not OK to be in pain. We have options that may work better, so don’t be afraid to ask.
 

Taking control 

My previous product had a 4-hour half-life, which made managing my hemophilia challenging. With ALTUVIIIO, which allows me to infuse just once a week, I feel like I have more control over my hemophilia.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Chris I is a promotional speaker compensated by Sanofi and received free product through Sanofi’s Support Program.

Discover More Patient Experiences

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2508205-v1.0-11/2025 Last Updated: November 2025